RIT1

Summary

Gene Symbol: RIT1
Description: Ras like without CAAX 1
Alias: NS8, RIBB, RIT, ROC1, GTP-binding protein Rit1, GTP-binding protein Roc1, Ric-like, expressed in many tissues, ras-like protein expressed in many tissues, ras-like without CAAX protein 1
Species: human
Products:     RIT1

Top Publications

  1. O Steen S, Green D, Gopal A, Orozco J, Kenoyer A, Lin Y, et al. Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. Cancer Res. 2017;77:3885-3893 pubmed publisher
    ..We tested B-NHL responses to venetoclax combined with either external beam radiotherapy or radioimmunotherapy (RIT), which joins the selectivity of antibody targeting with the effectiveness of irradiation...
  2. Song I, Noh Y, Kwon J, Jung J, Lee B, Kim K, et al. Immuno-PET imaging based radioimmunotherapy in head and neck squamous cell carcinoma model. Oncotarget. 2017;8:92090-92105 pubmed publisher
    ..study, we evaluated the feasibility of immuno-positron emission tomography (PET) imaging and radioimmunotherapy (RIT) with 64Cu-/177Lu-PCTA-cetuximab in cetuximab-resistant SNU-1066 HNSCC xenografted model...
  3. Bouchelouche K, Tagawa S, Goldsmith S, Turkbey B, Capala J, Choyke P. PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Semin Nucl Med. 2011;41:29-44 pubmed publisher
    ..Prostate cancer represents an attractive target for radioimmunotherapy (RIT) for several reasons, including pattern of metastatic spread (lymph nodes and bone marrow, sites with good access ..
  4. Halime Z, Frindel M, Camus N, Orain P, Lacombe M, Bernardeau K, et al. New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and (64)Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative. Org Biomol Chem. 2015;13:11302-14 pubmed publisher
    ..have indeed a growing interest in nuclear medicine for positron emission tomography (PET) and radioimmunotherapy (RIT) where they show in several cases better complexation properties than dota or dota-like macrocycles, especially ..
  5. Santana A, Oldenburg D, Kirillov V, Malik L, Dong Q, Sinayev R, et al. RTA Occupancy of the Origin of Lytic Replication during Murine Gammaherpesvirus 68 Reactivation from B Cell Latency. Pathogens. 2017;6: pubmed publisher
    ..with host NF-kappaB (NF-?B) signaling during murine gammaherpesvirus 68 (MHV68) infection: a latent B cell line (HE-RIT) inducible for RTA-Flag expression and virus reactivation; and a recombinant virus (MHV68-RTA-Bio) that enabled in ..
  6. Weber T, Bötticher B, Mier W, Sauter M, Krämer S, Leotta K, et al. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab. Eur J Nucl Med Mol Imaging. 2016;43:489-98 pubmed publisher
    ..For radioimmunotherapy (RIT) studies, non-obese diabetic recombination activating gene-1 (NOD-Rag1 (null) ) interleukin-2 receptor common gamma ..
  7. Bielskiene K, Bagdoniene L, Mozūraitienė J, Kazbariene B, Janulionis E. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma. Medicina (Kaunas). 2015;51:1-9 pubmed publisher
    ..Components of different E3 ligases complexes (FBW7, MDM2, RBX1/ROC1, RBX2/ROC2, cullins and many others) are known as oncogenes or tumor suppressors in melanomagenesis...
  8. Bodet Milin C, Kraeber Bodéré F, Eugène T, Guérard F, Gaschet J, Bailly C, et al. Radioimmunotherapy for Treatment of Acute Leukemia. Semin Nucl Med. 2016;46:135-46 pubmed publisher
    ..However, published results of immunotherapy alone are generally modest. Radioimmunotherapy (RIT) brings additional therapeutic mechanisms using radiolabeled monoclonal antibodies (mAbs) directed to tumor ..
  9. Yeung S, Tong J, Law P, Chung L, Lung R, Tong C, et al. Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor. J Thorac Oncol. 2015;10:1292-1300 pubmed publisher
    ..154 lung adenocarcinomas and adenosquamous carcinomas for EGFR, KRAS, HER2, BRAF, PIK3CA, MET, NRAS, MAP2K1, and RIT1 mutations by polymerase chain reaction-direct sequencing...

More Information

Publications122 found, 100 shown here

  1. Zhang N, Guan F, Zhang Y, Li Q, Xu Y, Yang L, et al. RING box protein-1 gene involved in flagellar disassembly of Dunaliella salina. Folia Microbiol (Praha). 2017;62:57-62 pubmed publisher
    Ring box protein-1 (RBX1), also called Regulator of Cullins-1 (ROC1), is a key component of SCF (Skp-1, cullins, F-box proteins) E3 ubiquitin ligases, which regulate diverse cellular processes by targeting protein substrates for ..
  2. Kesavan M, Boucek J, MacDonald W, McQuillan A, Turner J. Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy. Diagnostics (Basel). 2017;7: pubmed publisher
    The purpose of this study was to evaluate prediction of prognosis after first-line radioimmunotherapy (RIT) of advanced follicular non-Hodgkin lymphoma (FL), by imaging with fluorine-18-fluorodeoxyglucose positron emission tomography ..
  3. Mbang Benet D, Sterkers Y, Crobu L, Sarrazin A, Bastien P, Pagès M. RNA interference screen reveals a high proportion of mitochondrial proteins essential for correct cell cycle progress in Trypanosoma brucei. BMC Genomics. 2015;16:297 pubmed publisher
    ..with those obtained by "high-throughput phenotyping using parallel sequencing of RNA interference targets" (RIT-seq). Nevertheless, a detailed analysis revealed many qualitative discrepancies with the RIT-seq-based approach...
  4. Leyton J, Williams B, Gao C, Keating A, Minden M, Reilly R. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells. Leuk Res. 2014;38:1367-73 pubmed publisher
    ..translocation sequence (NLS) peptides to enable nuclear importation in LSCs for Auger electron radioimmunotherapy (RIT) of AML...
  5. Reagan P, Friedberg J. Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma. Curr Treat Options Oncol. 2015;16:32 pubmed publisher
    ..Radioimmunotherapy (RIT) has similarly shown efficacy in low tumor burden disease...
  6. Lam R, Fung Y, Han W, Yu K. Rescue effects: irradiated cells helped by unirradiated bystander cells. Int J Mol Sci. 2015;16:2591-609 pubmed publisher
    ..The rescue effect can compromise the efficacy of radioimmunotherapy (RIT) (and actually all radiotherapy)...
  7. Uike N, Choi I, Tsuda M, Haji S, Toyoda K, Suehiro Y, et al. Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era. Int J Hematol. 2014;100:386-92 pubmed publisher
    This retrospective study analyzes the results of radioimmunotherapy (RIT) with (90)Y-ibritumomab tiuxetan in 94 Japanese patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma at a single institution...
  8. Cai Q, Li J. [Association of CRBN Gene with Immunomodulatory Drug Resis- tance in Multiple Myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23:892-7 pubmed publisher
    ..3 at 3p26 and its encoding protein is a member of E3 ubiquitin ligase complex (composed of CRBN, DDB1, CUL4A and ROC1)...
  9. Uddin S, Bhat A, Krishnankutty R, Mir F, Kulinski M, Mohammad R. Involvement of F-BOX proteins in progression and development of human malignancies. Semin Cancer Biol. 2016;36:18-32 pubmed publisher
    ..of E3 Ub ligases, the SCF (Skp-Cullin-F-box) complex, is composed of four principal components: Skp1, Cul1/Cdc53, Roc1/Rbx1/Hrt1, and an F-box protein (FBP)...
  10. Muselaers C, Boers Sonderen M, van Oostenbrugge T, Boerman O, Desar I, Stillebroer A, et al. Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. Eur Urol. 2016;69:767-70 pubmed publisher
    ..A phase 2 radioimmunotherapy (RIT) trial with lutetium 177 ((177)Lu)-girentuximab was initiated to evaluate the efficacy of this approach...
  11. Evans Axelsson S, Timmermand O, Bjartell A, Strand S, Elgqvist J. Radioimmunotherapy for Prostate Cancer--Current Status and Future Possibilities. Semin Nucl Med. 2016;46:165-79 pubmed publisher
    ..have been conducted, or are ongoing, to investigate the therapeutic efficacy and toxicity of radioimmunotherapy (RIT) against PCa...
  12. Murphy C, Xu Y, Li F, Nio K, Reszka Blanco N, Li X, et al. Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication. Cell Rep. 2016;16:2846-2854 pubmed publisher
    ..Interaction of HBx with the DDB1-CUL4-ROC1 (CRL4) E3 ligase is critical for this function...
  13. Rao F, Xu J, Khan A, Gadalla M, Cha J, Xu R, et al. Inositol hexakisphosphate kinase-1 mediates assembly/disassembly of the CRL4-signalosome complex to regulate DNA repair and cell death. Proc Natl Acad Sci U S A. 2014;111:16005-10 pubmed publisher
    ..CRL4, comprising the scaffold Cullin 4A/B, the E2-interacting Roc1/2, and the adaptor protein damage-specific DNA-binding protein 1, is activated by DNA damage...
  14. Kasten B, Arend R, Katre A, Kim H, Fan J, Ferrone S, et al. B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol. 2017;47:23-30 pubmed publisher
    ..expressed on ovarian cancer cells and CICs, as a carrier molecule for targeted α-particle radioimmunotherapy (RIT) in preclinical models of human ovarian cancer. mAb 376...
  15. Holthausen F, von Müller F, Happel C, Kranert W, Grünwald F. Age and body composition influence TSH concentrations after administration of rhTSH. Nuklearmedizin. 2015;54:20-5 pubmed publisher
    ..106 patients with differentiated thyroid cancer (DTC) undergoing radioiodine therapy (RIT) after rhTSH administration were obtained through chart review...
  16. Fan W, Fan Z, Yang M, Pan Y, Bai H. [Molecular Mechanism of CRBN in the Activity of Lenalidomid eagainst Myeloma--Review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018;26:1240-1243 pubmed publisher
    ..which interacts with DNA damage-binding protein-1 (DDB1), Cullin 4 (Cul4A or Cul4B), and regulator of Cullins 1 (RoC1) to form the functional E3 ubiquitin ligase complex(CRBN-CRL4) that performs proteolysis via the ubiquitin-..
  17. Salleras L, Salleras M, Soldevila N, Prat A, Garrido P, Domínguez Ã. [Vaccines against varicella-zoster virus (VZV)]. Enferm Infecc Microbiol Clin. 2015;33:411-23 pubmed publisher
    ..two attenuated varicella vaccines derived from the OKA strain are licensed: Varilrix® GlaxoSmithKline (OKA/RIT strain) and Varivax® Merck Sharp and Dohme (OKA/Merck strain)...
  18. Alewine C, Xiang L, Yamori T, Niederfellner G, Bosslet K, Pastan I. Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers. Mol Cancer Ther. 2014;13:2653-61 pubmed publisher
    The RG7787 mesothelin-targeted recombinant immunotoxin (RIT) consists of an antibody fragment targeting mesothelin (MSLN) fused to a 24-kD fragment of Pseudomonas exotoxin A for cell killing...
  19. Kirby J, Nishimoto M, Chow R, Baidoo E, Wang G, Martin J, et al. Enhancing Terpene yield from sugars via novel routes to 1-deoxy-d-xylulose 5-phosphate. Appl Environ Microbiol. 2015;81:130-8 pubmed publisher
    ..coli yajO gene, annotated as a putative xylose reductase, or via various mutations in the native ribB gene...
  20. Nakagawa T, Lv L, Nakagawa M, Yu Y, Yu C, D Alessio A, et al. CRL4(VprBP) E3 ligase promotes monoubiquitylation and chromatin binding of TET dioxygenases. Mol Cell. 2015;57:247-260 pubmed publisher
    ..Here we show that all three TET proteins bind to VprBP and are monoubiquitylated by the VprBP-DDB1-CUL4-ROC1 E3 ubiquitin ligase (CRL4(VprBP)) on a highly conserved lysine residue...
  21. Vallabhajosula S, Nikolopoulou A, Jhanwar Y, Kaur G, Tagawa S, Nanus D, et al. Radioimmunotherapy of Metastatic Prostate Cancer with ¹??Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. Curr Radiopharm. 2016;9:44-53 pubmed
    ..data in PSMA positive xenografts, strongly suggested that 177;Lu-J591 mAb is an ideal radiopharmaceutical for RIT of metastatic PCa...
  22. King E, Mazor R, Çuburu N, Pastan I. Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin. J Immunol. 2018;200:2038-2045 pubmed publisher
    ..Here, we evaluated the efficacy of methotrexate (MTX) to prevent ADA formation against the mesothelin-targeting RIT LMB-100 in naive mice and in mice with pre-existing Abs...
  23. McCoach C, Le A, Gowan K, Jones K, Schubert L, Doak A, et al. Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res. 2018;24:3334-3347 pubmed publisher
    ..gene fusion, a RET fusion, 2 EGFR, and 3 KRAS mutations, as well as mutations in IDH1, RIT1, NOTCH, and NF1 In addition, we identified CNV in multiple proto-oncogenes genes including PDGFRA, ..
  24. Diaz Moreno R, Venencia D, Garrigo E, Pipman Y. A method to enhance spatial resolution of a 2D ion chamber array for quality control of MLC. J Appl Clin Med Phys. 2011;12:3456 pubmed publisher
    ..The same patterns were exposed on radiographic film and analyzed with the RIT software for validation...
  25. Hadid T, Raufi A, Kafri Z, Mandziara M, Kalabat J, Szpunar S, et al. Safety and efficacy of radioimmunotherapy (RIT) in treatment of non-Hodgkin's lymphoma in the community setting. Nucl Med Biol. 2016;43:227-31 pubmed publisher
    Radioimmunotherapy (RIT) is a unique therapeutic modality that combines biologic and radiolytic mechanisms to induce tumor kill. RIT is underutilized in the community outpatient setting...
  26. Tomblyn M, Katin M, Wallner P. The new golden era for radioimmunotherapy: not just for lymphomas anymore. Cancer Control. 2013;20:60-71 pubmed
    Radioimmunotherapy (RIT) has been approved for the treatment of B-cell non-Hodgkin lymphomas in the United States for more than a decade...
  27. Kaplan G, Lee F, Onda M, Kolyvas E, Bhardwaj G, Baker D, et al. Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A. Toxins (Basel). 2016;8: pubmed publisher
    ..The most active of these, SS1-Fab-DS3-PE24, shows a longer serum half-life than an RIT without the disulfide bond and has the same anti-tumor activity, despite being less cytotoxic in vitro...
  28. Kasten B, Oliver P, Kim H, Fan J, Ferrone S, Zinn K, et al. 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci. 2018;19: pubmed publisher
    ..The purpose of this study was to determine whether ?-particle radioimmunotherapy (RIT) targeting TNBC cells using the CSPG4-specific monoclonal antibody (mAb) 225...
  29. Phaeton R, Jiang Z, Revskaya E, Fisher D, Goldberg G, Dadachova E. Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer. Cancer Med. 2016;5:9-16 pubmed publisher
    ..Therefore, more efficacious treatments are needed. We are developing radioimmunotherapy (RIT) of HPV-positive cervical cancers by targeting E6 and E7 viral oncoproteins expressed by the cancer cells with the ..
  30. Mir S, Cai W, Andres D. RIT1 GTPase Regulates Sox2 Transcriptional Activity and Hippocampal Neurogenesis. J Biol Chem. 2017;292:2054-2064 pubmed publisher
    ..Here we report that the Ras-related GTPase RIT1 serves to control the sequential proliferation and differentiation of adult hippocampal neural progenitor cells, ..
  31. Edizer D, Bilici S, Yıldız M, Yigit O, Cermik T. Short-term Effects of Radioiodine Therapy on Auditory Function. J Int Adv Otol. 2017;: pubmed publisher
    Radioiodine therapy (RIT) is frequently utilized as an adjunctive treatment option for differentiated thyroid carcinoma following surgical intervention...
  32. Sabet A, Binse I, Dogan S, Koch A, Rosenbaum Krumme S, Biersack H, et al. Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2017;44:190-195 pubmed publisher
    ..All patients were treated with the same protocol consisting of ablative radioiodine therapy (RIT, 3.7 GBq) and one post-ablation treatment after 3 months (3.7-11.1 GBq)...
  33. Howe J, Wang H, Fischmann T, Balibar C, Xiao L, Galgoci A, et al. Selective small-molecule inhibition of an RNA structural element. Nature. 2015;526:672-7 pubmed publisher
    ..structurally distinct synthetic mimic of the natural ligand, flavin mononucleotide, to repress riboswitch-mediated ribB gene expression and inhibit bacterial cell growth...
  34. Mir S, Cai W, Carlson S, Saatman K, Andres D. IGF-1 mediated Neurogenesis Involves a Novel RIT1/Akt/Sox2 Cascade. Sci Rep. 2017;7:3283 pubmed publisher
    ..Here, we demonstrate that the Ras-related GTPase, RIT1, plays a critical role in IGF-1-dependent neurogenesis...
  35. Leung G, Luk H, Tang V, Gao W, Mak C, Yu M, et al. Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies. Sci Rep. 2018;8:2421 pubmed publisher
    ..Four VUSs were identified in five patients. The functional assessment supported the pathogenicity of the RAF1 and RIT1 VUSs, while the significance of two VUSs in A2ML1 remained unclear...
  36. Bian S, Li X, Mainali H, Chen L, Dhaubhadel S. Genome-wide analysis of DWD proteins in soybean (Glycine max): Significance of Gm08DWD and GmMYB176 interaction in isoflavonoid biosynthesis. PLoS ONE. 2017;12:e0178947 pubmed publisher
    A subset of WD40 proteins with DWD motif has been proposed to serve as substrate receptor of DDB-CUL4-ROC1 complex, thereby getting involved in protein degradation via ubiquitination pathway...
  37. Akuffo A, Alontaga A, Metcalf R, Beatty M, Becker A, McDaniel J, et al. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. J Biol Chem. 2018;293:6187-6200 pubmed publisher
    ..drugs, the E3 ligase substrate receptor cereblon (CRBN) promotes proteosomal destruction by engaging the DDB1-CUL4A-Roc1-RBX1 E3 ubiquitin ligase in human cells but not in mouse cells, suggesting that sequence variations in CRBN may ..
  38. Jovanovic M, Svrakic D. Integrative Treatment of Personality Disorder. Part I: Psychotherapy. Psychiatr Danub. 2017;29:2-13 pubmed
    ..We introduce our original method of psychotherapy, called reconstructive interpersonal therapy (RIT)...
  39. Milenic D, Baidoo K, Kim Y, Barkley R, Brechbiel M. Targeted ?-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab. Transl Oncol. 2017;10:535-545 pubmed publisher
    ..e., monoclonal antibodies (mAb) and their various forms, for radioimmunotherapy (RIT) remains an active area of research...
  40. Hosseini S, Aboudzadeh M, Sadeghi M, Ahmadi Teymourlouy A, Rostampour M. Assessment and estimation of 67Cu production yield via deuteron induced reactions on natZn and 70Zn. Appl Radiat Isot. 2017;127:137-141 pubmed publisher
    sup>67Cu radioisotope is a beta particle-emitting nuclide used in radioimmunotherapy (RIT) as well as for imaging, tracer kinetic studies and dosimetry. 67Cu can be produced by bombarding natZn with deuterons...
  41. Biton Y, Huang D, Goldenberg I, Rosero S, Moss A, Kutyifa V, et al. Relationship between age and inappropriate implantable cardioverter-defibrillator therapy in MADIT-RIT (Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy). Heart Rhythm. 2016;13:888-93 pubmed publisher
    ..In the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) 1500 patients were randomized to 3 ICD programming arms: (A) conventional with ventricular tachycardia (VT) ..
  42. Pasternak A, Szura M, Solecki R, Matyja M, Szczepanik A, Matyja A. Impact of responsive insertion technology (RIT) on reducing discomfort during colonoscopy: randomized clinical trial. Surg Endosc. 2017;31:2247-2254 pubmed publisher
    ..The variable stiffness of the endoscope and the recently introduced responsive insertion technology (RIT) are features aimed at easing colonoscope insertion and reducing the discomfort and pain during the examination...
  43. Tao Y, Zhu L, Zhao Y, Yi X, Zhu L, Ge F, et al. Nano-graphene oxide-manganese dioxide nanocomposites for overcoming tumor hypoxia and enhancing cancer radioisotope therapy. Nanoscale. 2018;10:5114-5123 pubmed publisher
    ..labeled rGO-MnO2-PEG nanocomposites as therapeutic agents for in vivo tumor radioisotope therapy (RIT), achieving excellent tumor killing and further enhancing the therapeutic efficiency of RIT...
  44. Wei J, Bera T, Liu X, Zhou Q, Onda M, Ho M, et al. Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity. Proc Natl Acad Sci U S A. 2018;115:E3501-E3508 pubmed publisher
    ..was shown to be effective in treating patients with some leukemias, where the cells are readily accessible to the RIT. However, their short half-life limits their efficacy in solid tumors, because penetration into the tumors is slow...
  45. Shimoni A, Zwas S. Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma. Semin Nucl Med. 2016;46:119-25 pubmed publisher
    ..Novel approaches are needed for these high-risk patients, especially in the rituximab era. Radioimmunotherapy (RIT) is a form of targeted therapy using the parent monoclonal antibody to deliver radiation emitted by a conjugated ..
  46. Milenic D, Baidoo K, Kim Y, Barkley R, Brechbiel M. Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease. Dalton Trans. 2017;46:14591-14601 pubmed publisher
    ..comparing 211At, 227Th, 213Bi and 212Pb, the choice of radionuclide for RIT is perhaps not entirely based on simple therapeutic efficacy, other factors may play a role in choosing the "right" ..
  47. Laíns I, Miller J, Park D, Tsikata E, Davoudi S, Rahmani S, et al. Structural Changes Associated with Delayed Dark Adaptation in Age-Related Macular Degeneration. Ophthalmology. 2017;124:1340-1352 pubmed publisher
    ..The primary outcome was rod-intercept time (RIT), defined in minutes, as a continuous variable...
  48. Mo Y, Lin R, Liu P, Tan M, Xiong Y, Guan K, et al. SIRT7 deacetylates DDB1 and suppresses the activity of the CRL4 E3 ligase complexes. FEBS J. 2017;284:3619-3636 pubmed publisher
    Cullin 4 (CUL4) and small ring finger protein ROC1 assemble to form E3 ubiquitin ligase (CRL4) complexes...
  49. Han Y, Jeong H, Sohn M, Lee S, Lim S. Radioiodine ablation in thyroid cancer patients: renal function and external radiation dose rate at discharge according to patient preparation. Q J Nucl Med Mol Imaging. 2018;: pubmed publisher
    ..into thyroid remnants and residual thyroid cancer in patients undergoing high-dose radioiodine therapy (HD-RIT)...
  50. Li N, Zhu H, Li Y, Wang J, Yang Z. Synthesis and evaluation of Cy5.5-Rit tracer for specific near-infrared fluorescence imaging of sentinel lymph node. Bioorg Med Chem Lett. 2016;26:4233-6 pubmed publisher
    ..Here we reported the new use of a conjugate, Cy5.5-Rituximab (Cy5.5-Rit), which is specific toward the CD20 receptor, as an imaging agent for non-invasive near-infrared fluorescence (NIRF)..
  51. Patra M, Zarschler K, Pietzsch H, Stephan H, Gasser G. New insights into the pretargeting approach to image and treat tumours. Chem Soc Rev. 2016;45:6415-6431 pubmed
    ..monoclonal antibodies (mAbs) for both non-invasive cancer radioimmunodetection (RID) and radioimmunotherapy (RIT)...
  52. Mazor R, Zhang J, Xiang L, Addissie S, Awuah P, Beers R, et al. Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors. Mol Cancer Ther. 2015;14:2789-96 pubmed publisher
    SS1P is a recombinant immunotoxin (RIT) that targets mesothelin. It consists of an antimesothelin Fv fused to a portion of Pseudomonas exotoxin A...
  53. Sekulić V, Rajić M, Vlajković M, Ilić S, Stević M, Kojić M. Short term treatment with lithium carbonate as adjunct to radioiodine treatment for long-lasting Graves' hyperthyroidism. Hell J Nucl Med. 2015;18:186-8 pubmed publisher
    ..Till now, the influence of LiCO₃on RIT outcome was mainly studied in patients with recent onset of GHT, and results were contradicted...
  54. Kuhlmann L, Freestone D, Manton J, Heyse B, Vereecke H, Lipping T, et al. Neural mass model-based tracking of anesthetic brain states. Neuroimage. 2016;133:438-456 pubmed publisher
    ..model-based tracking of brain states using the unscented Kalman filter applied to estimate parameters of the Jansen-Rit cortical population model is evaluated through the application of propofol-based anesthetic state monitoring...
  55. Xu F, Sun S, Yan S, Guo H, Dai M, Teng Y. Elevated expression of RIT1 correlates with poor prognosis in endometrial cancer. Int J Clin Exp Pathol. 2015;8:10315-24 pubmed
    b>RIT1, (Ras-like without CAAX1), the founding member of a novel branch of the Ras subfamily, mediates a wide variety of cellular functions, including cell proliferation, survival, and differentiation, and it may play crucial oncogenic role ..
  56. Schröfelbauer B, Hakata Y, Landau N. HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. Proc Natl Acad Sci U S A. 2007;104:4130-5 pubmed
    ..The interaction with DDB1 may explain several of the diverse biological functions of Vpr and suggests potential roles for Vpr in HIV-1 replication. ..
  57. Romani B, Engelbrecht S. Human immunodeficiency virus type 1 Vpr: functions and molecular interactions. J Gen Virol. 2009;90:1795-805 pubmed publisher
    ..Due to the critical role of Vpr in HIV-1 pathogenicity, study of the interactions between Vpr and cellular proteins may help us to understand the mechanism(s) of HIV-1 pathogenicity. ..
  58. Shi G, Cai W, Andres D. Rit-mediated stress resistance involves a p38-mitogen- and stress-activated protein kinase 1 (MSK1)-dependent cAMP response element-binding protein (CREB) activation cascade. J Biol Chem. 2012;287:39859-68 pubmed publisher
    ..Recent studies have identified the Ras-related small G-protein, Rit, as a central regulator of a p38-MK2-HSP27 signaling cascade that functions as a critical survival mechanism for ..
  59. Koenighofer M, Hung C, McCauley J, Dallman J, Back E, Mihalek I, et al. Mutations in RIT1 cause Noonan syndrome - additional functional evidence and expanding the clinical phenotype. Clin Genet. 2016;89:359-66 pubmed publisher
    ..Recently, mutations in RIT1 were identified as a novel cause for Noonan syndrome...
  60. Lee Y, Yuan W, Ho H, Chen C, Shih H, Chen R. The Cullin 3 substrate adaptor KLHL20 mediates DAPK ubiquitination to control interferon responses. EMBO J. 2010;29:1748-61 pubmed publisher
    ..KLHL20 binds DAPK and Cullin 3 (Cul3) via its Kelch-repeat domain and BTB domain, respectively. The KLHL20-Cul3-ROC1 E3 ligase complex promotes DAPK polyubiquitination, thereby inducing the proteasomal degradation of DAPK...
  61. Milosavljević D, Overwater E, Tamminga S, de Boer K, Elting M, van Hoorn M, et al. Two cases of RIT1 associated Noonan syndrome: Further delineation of the clinical phenotype and review of the literature. Am J Med Genet A. 2016;170:1874-80 pubmed publisher
    Mutations in RIT1, involved in the RAS-MAPK pathway, have recently been identified as a cause for Noonan syndrome...
  62. Koziolová E, Janouskova O, Cuchalová L, Hvězdová Z, Hrabeta J, Eckschlager T, et al. Overcoming multidrug resistance in Dox-resistant neuroblastoma cell lines via treatment with HPMA copolymer conjugates containing anthracyclines and P-gp inhibitors. J Control Release. 2016;233:136-46 pubmed publisher
    ..drugs doxorubicin (Dox) or pirarubicin (THP), P-gp inhibitors derived from reversin 121 (REV) or ritonavir (RIT)), or both anticancer drug and P-gp inhibitor were designed and synthesized...
  63. Higgins R, Hogg P, Robinson L. Constructive alignment of a research-informed teaching activity within an undergraduate diagnostic radiography curriculum: A reflection. Radiography (Lond). 2017;23 Suppl 1:S30-S36 pubmed publisher
    To evaluate the learning experience of a level 5 (year 2) student cohort within a research-informed teaching (RiT) activity and to map findings against learning outcomes and level descriptors using constructive alignment...
  64. Shao H, Kadono Okuda K, Finlin B, Andres D. Biochemical characterization of the Ras-related GTPases Rit and Rin. Arch Biochem Biophys. 1999;371:207-19 pubmed
    We report the biochemical characterization of Rit and Rin, two members of the Ras superfamily identified by expression cloning. Recombinant Rit and Rin bind GTP and exhibit intrinsic GTPase activity...
  65. Toledo M, Vanlerberghe V, Rosales J, Mirabal M, Cabrera P, Fonseca V, et al. The additional benefit of residual spraying and insecticide-treated curtains for dengue control over current best practice in Cuba: Evaluation of disease incidence in a cluster randomized trial in a low burden setting with intensive routine control. PLoS Negl Trop Dis. 2017;11:e0006031 pubmed publisher
    ..trial in Santiago de Cuba to evaluate the entomological and epidemiological effectiveness of periodical intra- and peri-domiciliary residual insecticide (deltamethrin) treatment (RIT) and long lasting insecticide treated curtains (ITC).
  66. Li J, Liu W, Kuang Z, Zhang R, Chen H, Feng Q. [Mutation and amplification of RIT1 gene in hepatocellular carcinoma]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2004;21:43-6 pubmed
    To explore the mutation and amplification of RIT1 gene and their correlation with carcinogenesis of hepatocellular carcinoma (HCC)...
  67. Martinez A, Martínez Ramírez M, Martínez Caballero D, Beneit P, Clavel J, Figueroa G, et al. Radioimmunotherapy for non-Hodgkin's lymphoma; positioning, safety, and efficacy of 90Y-Ibritumomab. 10 years of experience and follow-up. Rev Esp Med Nucl Imagen Mol. 2017;36:13-19 pubmed publisher
    Radioimmunotherapy (RIT) is one of the therapies directed against molecular targets in non-Hodgkin's lymphoma (NHL). To evaluate the positioning, safety, and effectiveness of RIT with 90Y-Ibritumomab in NHL patients...
  68. Ferguson J, Wu Y, Smith K, Charles P, Powers K, Wang H, et al. ASB4 is a hydroxylation substrate of FIH and promotes vascular differentiation via an oxygen-dependent mechanism. Mol Cell Biol. 2007;27:6407-19 pubmed
    ..We postulate that hydroxylation of ASB4 in normoxia promotes binding to and degradation of substrate protein(s) to modulate vascular differentiation. ..
  69. Nemcikova M, Vejvalkova S, Fencl F, Sukova M, Krepelova A. A novel heterozygous RIT1 mutation in a patient with Noonan syndrome, leukopenia, and transient myeloproliferation-a review of the literature. Eur J Pediatr. 2016;175:587-92 pubmed publisher
    ..Recently, missense mutations in RIT1 have been reported as causative for individuals with clinical signs of NS. We report on a 2...
  70. Bafor E, Rowan E, Edrada Ebel R. Toward Understanding Myometrial Regulation: Metabolomic Investigation Reveals New Pathways of Oxytocin and Ritodrine Activity on the Myometrium. Reprod Sci. 2017;24:691-705 pubmed publisher
    ..aimed at investigating the possibility of other pathways involved in the activities of both OT and ritodrine (RIT; a ?-adrenergic agonist) in the myometrium by utilizing metabolomics and bioinformatics...
  71. Heryanto Y, Hanaoka H, Nakajima T, Yamaguchi A, Tsushima Y. Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts. Ann Nucl Med. 2017;31:669-677 pubmed publisher
    Radioimmunotherapy (RIT) has proven effective for patients with relapsed and refractory lymphoma. However, new types of therapy are strongly desired as B-cell lymphoma remains incurable for many patients...
  72. Popp B, Ekici A, Thiel C, Hoyer J, Wiesener A, Kraus C, et al. Exome Pool-Seq in neurodevelopmental disorders. Eur J Hum Genet. 2017;25:1364-1376 pubmed publisher
    ..2016) (ACTB, AHDC1, ANKRD11, ATP6V1B2, ATRX, CASK, CHD8, GNAS, IFIH1, KCNQ2, KMT2A, KRAS, MAOA, MED12, MED13L, RIT1, SETD5, SIN3A, TCF4, TRAPPC11, TUBA1A, WAC, ZBTB18, ZMYND11), two in 543 (SysID) candidate genes (ZNF292, BPTF), ..
  73. Fang Z, Marshall C, Yin J, Mazhab Jafari M, Gasmi Seabrook G, Smith M, et al. Biochemical Classification of Disease-associated Mutants of RAS-like Protein Expressed in Many Tissues (RIT1). J Biol Chem. 2016;291:15641-52 pubmed publisher
    RAS-like protein expressed in many tissues 1 (RIT1) is a disease-associated RAS subfamily small guanosine triphosphatase (GTPase)...
  74. Lee C, Della N, Chew C, Zack D. Rin, a neuron-specific and calmodulin-binding small G-protein, and Rit define a novel subfamily of ras proteins. J Neurosci. 1996;16:6784-94 pubmed
    cDNAs encoding two novel 25 kDa Ras-like proteins, Rit and Rin, were isolated from mouse retina using a degenerate PCR-based cloning strategy. Using the expressed sequence tag database, human orthologs were also obtained and sequenced...
  75. Hacker K, LEE C, Rathmell W. VHL type 2B mutations retain VBC complex form and function. PLoS ONE. 2008;3:e3801 pubmed publisher
    ..We additionally demonstrated that Type 2B mutant pVHL forms a remnant VBC complex containing the active members ROC1 and Cullin-2 which retains the ability to ubiquitylate HIF-1alpha...
  76. Yaoita M, Niihori T, Mizuno S, Okamoto N, Hayashi S, Watanabe A, et al. Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations. Hum Genet. 2016;135:209-22 pubmed publisher
    ..We have recently identified mutations in RIT1 in patients with NS...
  77. Johari Doha F, Rahmani S, Rikhtechi P, Rasaneh S, Sheikholislam Z, Shahhosseini S. Development of DOTA-Rituximab to be Labeled with 90Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma. Iran J Pharm Res. 2017;16:619-629 pubmed
    ..cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radionuclide coupled to anti-CD20 antibody...
  78. Rondou P, Haegeman G, Vanhoenacker P, Van Craenenbroeck K. BTB Protein KLHL12 targets the dopamine D4 receptor for ubiquitination by a Cul3-based E3 ligase. J Biol Chem. 2008;283:11083-96 pubmed publisher
  79. Sonuga Barke E, Lasky Su J, Neale B, Oades R, Chen W, Franke B, et al. Does parental expressed emotion moderate genetic effects in ADHD? An exploration using a genome wide association scan. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:1359-68 pubmed publisher
    ..We find evidence for the role of EE in moderating the effects of genes on ADHD severity and comorbid conduct disorder, implicating both novel and established candidates. These findings need replicating in larger independent samples. ..
  80. Bertola D, Yamamoto G, Almeida T, Buscarilli M, Jorge A, Malaquias A, et al. Further evidence of the importance of RIT1 in Noonan syndrome. Am J Med Genet A. 2014;164A:2952-7 pubmed publisher
    ..Recently, a new gene (RIT1) was discovered as the causative gene in 17 of 180 Japanese individuals who were negative for the previously known ..
  81. Park H, Min J, Bom H, Kim J, Song H, Kwon S. Early stimulated thyroglobulin for response prediction after recombinant human thyrotropin-aided radioiodine therapy. Ann Nucl Med. 2017;: pubmed publisher
    ..However, due to the acute effect of I-131 on thyrocytes, Tg measured after radioiodine therapy (RIT) would not accurately reflect the thyroid tissue burden...
  82. Ableidinger M, Buckwar E, Hinterleitner H. A Stochastic Version of the Jansen and Rit Neural Mass Model: Analysis and Numerics. J Math Neurosci. 2017;7:8 pubmed publisher
    ..provide a useful framework for modelling mesoscopic neural dynamics and in this article we consider the Jansen and Rit neural mass model (JR-NMM)...
  83. Aung W, Tsuji A, Sudo H, Sugyo A, Ukai Y, Kouda K, et al. Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor. World J Gastroenterol. 2017;23:7551-7562 pubmed publisher
    To investigate the therapeutic effect of combined integrin ?6?4-targeted radioimmunotherapy (RIT) and PI3K/mTOR inhibitor BEZ235 in a pancreatic cancer model...
  84. Cai W, Rudolph J, Sengoku T, Andres D. Rit GTPase regulates a p38 MAPK-dependent neuronal survival pathway. Neurosci Lett. 2012;531:125-30 pubmed publisher
    b>Rit, along with Rin and Drosophila Ric, comprises the Rit subfamily of Ras-related small GTPases...
  85. Gómez Seguí I, Makishima H, Jerez A, Yoshida K, Przychodzen B, Miyano S, et al. Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies. Leukemia. 2013;27:1943-6 pubmed publisher
  86. Berger A, Imielinski M, Duke F, Wala J, Kaplan N, Shi G, et al. Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene. 2014;33:4418-23 pubmed publisher
    ..Here we report somatic mutations in the small GTPase gene RIT1 in ?2% of lung adenocarcinoma cases that cluster in a hotspot near the switch II domain of the protein...
  87. Livingston G, Escalona M, Foster A, Balajee A. Persistent in vivo cytogenetic effects of radioiodine therapy: a 21-year follow-up study using multicolor FISH. J Radiat Res. 2017;:1-8 pubmed publisher
    ..the peripheral blood lymphocytes of a 34-year-old male patient who received ablative radioactive 131iodine therapy (RIT) on two different occasions in 1992 and 1994...
  88. Daimee U, Vermilye K, Rosero S, Schuger C, Daubert J, Zareba W, et al. Heart failure severity, inappropriate ICD therapy, and novel ICD programming: a MADIT-RIT substudy. Pacing Clin Electrophysiol. 2017;: pubmed publisher
    ..We aimed to study the association between HF severity and inappropriate ICD therapy in MADIT-RIT.
  89. Palm S, Bäck T, Lindegren S, Hultborn R, Jacobsson L, Albertsson P. Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes. J Nucl Med. 2018;59:646-651 pubmed publisher
    ..This finding should also hold for other high-affinity mAbs and short-lived α-emitters. ..
  90. Hu J, Zacharek S, He Y, Lee H, Shumway S, Duronio R, et al. WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase. Genes Dev. 2008;22:866-71 pubmed publisher
    ..that TSC2 protein binds to FBW5, a DDB1-binding WD40 (DWD) protein, and is recruited by FBW5 to the DDB1-CUL4-ROC1 E3 ubiquitin ligase...
  91. Shi G, Cai W, Andres D. Rit subfamily small GTPases: regulators in neuronal differentiation and survival. Cell Signal. 2013;25:2060-8 pubmed publisher
    ..function for many "orphan" Ras-related GTPases remain poorly characterized, including members of the Rit subfamily GTPases...
  92. Gos M, Fahiminiya S, Poznański J, Klapecki J, Obersztyn E, Piotrowicz M, et al. Contribution of RIT1 mutations to the pathogenesis of Noonan syndrome: four new cases and further evidence of heterogeneity. Am J Med Genet A. 2014;164A:2310-6 pubmed publisher